Mereo BioPharma Group PLC ADR Total Liabilities
Mereo BioPharma Group PLC ADR total liabilities. Based on the latest financial reports, Mereo BioPharma Group PLC ADR (MREO) has total liabilities worth $6.06 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MREO asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Mereo BioPharma Group PLC ADR (2015–2025)
Total liabilities of Mereo BioPharma Group PLC ADR from 2015 to 2025. This chart illustrates how Mereo BioPharma Group PLC ADR's total liabilities have evolved over time, based on quarterly financial data.
Mereo BioPharma Group PLC ADR Competitors by Total Liabilities
The table below lists competitors of Mereo BioPharma Group PLC ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dardanel Onentas Gida Sanayi AS
IS:DARDL
|
Turkey | TL446.32 Million |
|
Rekor Systems Inc
NASDAQ:REKR
|
USA | $44.03 Million |
|
LightInTheBox Holding Co Ltd ARD
NYSE:LITB
|
USA | $65.74 Million |
|
Analabs Resources Bhd
KLSE:7083
|
Malaysia | RM305.62 Million |
|
SIL Investments Limited
NSE:SILINV
|
India | Rs-26.30 Billion |
|
Tritax Big Box REIT plc
LSE:BBOX
|
UK | GBX2.82 Billion |
|
Kalaris Therapeutics, Inc.
NASDAQ:KLRS
|
USA | $41.25 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Mereo BioPharma Group PLC ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Mereo BioPharma Group PLC ADR.
Liquidity & Leverage Metrics
Mereo BioPharma Group PLC ADR Total Liabilities Ratios Explained
Mereo BioPharma Group PLC ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mereo BioPharma Group PLC ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mereo BioPharma Group PLC ADR (2015–2025)
The table below shows the annual total liabilities of Mereo BioPharma Group PLC ADR from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.00 Million | -67.57% |
| 2024-12-31 | $15.42 Million | -3.39% |
| 2023-12-31 | $15.96 Million | -38.63% |
| 2022-12-31 | $26.01 Million | -49.93% |
| 2021-12-31 | $51.95 Million | -51.25% |
| 2020-12-31 | $106.55 Million | +74.13% |
| 2019-12-31 | $61.19 Million | +77.34% |
| 2018-12-31 | $34.51 Million | +1.93% |
| 2017-12-31 | $33.85 Million | +350.87% |
| 2016-12-31 | $7.51 Million | +30.42% |
| 2015-12-31 | $5.76 Million | -- |
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more